ライフサイエンスコーパス: creatinine

1 g creatinine) than for non-users (3.05 mug/g creatinine).

2 ere produced in situ from either acrolein or creatinine.

3 se, BMI z-score for age and sex, and urinary creatinine.

4 transferase, aspartate aminotransferase, and creatinine.

5 te reductase (DHFR) genotype and cord plasma creatinine.

6 serum creatinine, urea, cystatin-C, and urea creatinine.

7 her enhanced when combined with NT-proBNP or creatinine.

8 (NT-proBNP), urine output (UOP), and plasma creatinine.

9 ed the FOLP probe for its ability to monitor creatinine.

10 ile range) of SigmaAs was 4.2 (2.8-6.9) ug/g creatinine.

11 and on concentrations of crotonaldehyde and creatinine.

12 unction 3 years posttransplant (median serum creatinine 1.5 mg/dL).

13 unction at 24 months postindex biopsy (serum creatinine 1.75 mg/dl, geometric mean, vs class 2: P = .

14 (1.83 [1.21-2.77] per 5% increase) and serum creatinine (10.82 [1.49-78.69] per 1 mg/dL increase), pl

15 posure [total urinary As, mean (+/-SD) mug/g creatinine: 11.7 (10.6)].

16 compared with HAMP and SCS (mean peak serum creatinine: 3.66 +/- 1.33 mg/dL [postoperative d 1 [(POD

17 Primary endpoint was change of serum creatinine 48 h after PCI (Deltacreatinine).

18 ount >=13.0 x 103/muL (2.35 [1.17-4.72]) and creatinine (7.75 [1.20-50.16] per 1 mg/dL increase) conc

19 of less than 0.97 mmol/L (3.0 mg/dL); serum creatinine 8.8-35.4 mumol/L (0.1-0.4 mg/dL); radiographi

20 te kidney injury based on the level of serum creatinine above the upper limit of reference interval v

21 59 ml/min per 1.73 m(2) with urinary albumin/creatinine (ACR) >=50 mg/g and serum bicarbonate 20-28 m

22 23% of variation in recorded 6-month serum creatinine among obese donors was attributed to center (

23 or's cavity by means of competition with the creatinine analytes.

24 Weight, creatinine and ALT did not differ between groups.

25 baseline values for viral load and for serum creatinine and aminotransferase levels each correlated w

26 laboratory abnormalities, including elevated creatinine and aminotransferases, were mild and normaliz

27 nosis Consortium (CKD-PC) with data on serum creatinine and change in albuminuria and more than 50 ev

28 oduct of biochemical reactions for detecting creatinine and creatinine is an important biomarker for

29 uantified the associations of eGFR (based on creatinine and cystatin C) and ACR with cancer risk usin

30 erular filtration rate (eGFR) based on serum creatinine and cystatin C.

31 for the design of supramolecular sensors for creatinine and its lipophilic derivative hexylcreatinine

32 f clinical responder status were lower serum creatinine and KCCQ-OS scores and treatment assignment t

33 om specific centers have consistently higher creatinine and MELD-Na values.

34 rade 3 adverse events occurred; two elevated creatinine and one hypertension.

35 Patients with outpatient serum creatinine and potassium tests in the 30 days after star

36 ents at risk of having abnormally high serum creatinine and potassium values in follow-up.

37 perior to traditional AKI biomarkers such as creatinine and UOP.

38 pendent manner, significantly reducing serum creatinine and urea, tubular injury, neutrophil and macr

39 h during the 40% fat (2.50 +/- 0.37 mumol/g creatinine) and 0% fat (2.37 +/- 0.37 mumol/g creatinine

40 inopropanoate), ATP13A5 (with the metabolite creatinine) and DPYS (with the metabolites 3-ureidopropi

41 hemoglobin A(1c), blood urea nitrogen, serum creatinine), and socioeconomic factors (health insurance

42 Reactions involving reactive carbonyls, creatinine, and ammonia-producing compounds were investi

43 d graft function, primary nonfunction, serum creatinine, and biliary complications.

44 ncluding admission, peak, and terminal serum creatinine, and biopsy data when available to differenti

45 ed proteinuria, glomerular thrombosis, serum creatinine, and glomerular macrophage infiltration, with

46 ergy for MeIQ formation from crotonaldehyde, creatinine, and glutamine was 72.2 +/- 0.4 kJ.mol(-1).

47 minotransferase (AST), alkaline phosphatase, creatinine, and improved liver, and renal antioxidative

48 associated with anemia, hypoalbuminemia, low creatinine, and the use of supplemental oxygen (all P <

49 veloped a new PELD score using serum sodium, creatinine, and updated original PELD components to more

50 Tissue and urinary (corrected for creatinine) arsenic content was higher in domestic cats,

51 of inflammation, lactate dehydrogenase, and creatinine as the variables most predictive of respirato

52 ntages of current methods of (bio)sensing of creatinine, as well as an overview of the drawbacks that

53 .015), and paradoxically, better recovery of creatinine at 60 days ( P=0.01).

54 The study measured creatinine at enrollment and test of cure, serum gentami

55 with creatinine, with worsening agreement in creatinine at high bilirubin levels.

56 Elevated serum creatinine at the time of heart transplant is an indepen

57 remained significant when adjusted for serum creatinine at the time of the biopsy, Banff i, ci and ct

58 the ICU, we advocate for caution when using creatinine based estimated glomerular filtration rate eq

59 ine levels independently of GFR, the earlier creatinine-based contraindication may have inadvertently

60 re (Kidney Disease: Improving Global Outcome creatinine-based criteria).Measurements and Main Results

61 tion, with the lowest performance related to creatinine-based equations compared with cystatin C.

62 ients with diabetes and CKD from using serum creatinine-based thresholds to using eGFR-based threshol

63 f 30 patient serum samples were analyzed for creatinine, bilirubin, and sodium in all transplant cent

64 All parameters of renal function (serum creatinine, blood urea nitrogen, and electrolytes) were

65 er, laterality, insulin use, hemoglobin A1c, creatinine, blood urea nitrogen, and estimated glomerula

66 nal function, as indicated by elevated serum creatinine, BUN, and potassium.

67 (sub-AKI) refers to patients with low serum creatinine but elevated alternative biomarkers of AKI.

68 Creatinine- but not cystatin C-based estimations largely

69 , thiamine, N(1)-methylnicotinamide (1-NMN), creatinine, carnitine, and metformin, which is a probe f

70 High levels of urinary protein, creatinine, cholesterol, and platelets were independent

71 Medically ill patients with a baseline creatinine clearance >=50 ml/min were randomized in a do

72 ents with severe renal impairment (SRI, i.e. creatinine clearance < 30ml/min).

73 nic Health Evaluation II scores >15, 23% had creatinine clearance <60 mL/min, and 35% were aged >=65

74 % +/- 90%), urinary PO2 (+164% +/- 80%), and creatinine clearance (+120% +/- 65%) at 30 minutes.

75 urine volume (299 vs. 80 mL, p < 0.001) and creatinine clearance (161.4 vs. 123.4 mL/min, p = 0.03)

76 Creatinine clearance (CrCl) overestimated I-iothalamate

77 for this purpose [GFR measurement by urinary Creatinine Clearance (uCrCl) versus GFR estimation (eGFR

78 advanced chronic kidney disease (defined as creatinine clearance [CrCl] 25 to 30 mL/min) enrolled in

79 P group demonstrated significantly increased creatinine clearance calculated on POD3 (63.6 +/- 19.0 m

80 ry diffusion capacity of less than 80%, or a creatinine clearance of 30 mL/min or more but less than

81 clinical response in patients with baseline creatinine clearance of 30-50 mL/min, potentially due to

82 than 18 years and younger than 65 years with creatinine clearance of 30-69 mL/min (calculated by use

83 ative illness rating scale greater than 6, a creatinine clearance of 30-69 mL/min, or both.

84 al exposure in the previous 6 months, with a creatinine clearance of more than 60 mL/min (>80 mL per

85 of iohexol clearance toward 24-hour urinary creatinine clearance over the same period was -18.1 mL/m

86 The 24-hour creatinine clearance remains the mainstay for kidney fun

87 Urinary creatinine clearance underestimated renal impairment in

88 as 67.8 years, 55.5% were men, mean baseline creatinine clearance was 87.8 ml/min, and mean duration

89 In pooled analysis, baseline creatinine clearance was associated with observed TFV-DP

90 Eight-hour urine collections to measure creatinine clearance were collected daily as the primary

91 The total urine volume, creatinine clearance, and change in plasma renin activit

92 Donor age, body mass index, creatinine clearance, and ischemic time were independent

93 ard and kinetic equations as well as urinary creatinine clearance.

94 ing two boluses had no beneficial effects on creatinine clearance.

95 ondarily, we considered acute kidney injury (creatinine concentration >= 0.3 mg/dL or 1.5 times basel

96 dence interval: 0.96, 1.03) among women with creatinine concentration <=0.7 mg/dL and a history of hy

97 Mean serum creatinine concentration was 2.93 +/- 0.89 mg/dl at the

98 , -1.1%; P = 0.006) and reduction in urinary creatinine concentrations (-21.2%; 95% CI: -31.4, -9.5%;

99 pneumonia mortality among participants with creatinine-corrected urinary cadmium in the 80th vs. 20t

100 an follow-up of 17.3 y (NHANES-III, based on creatinine-corrected urine cadmium) and 11.4 y (NHANES 1

101 aminotransferase, lactate dehydrogenase, and creatinine correlated to fatality (odds ratios [ORs], 2.

102 demonstrated for the analytical detection of creatinine (CRE) in undiluted human urine.

103 We used serum creatinine criterion of KDIGO definition for diagnosis o

104 10 000 copies/mL was associated with a lower creatinine/cystatin C eGFR at 2 years post-HCT.

105 MeIQ formation, but ammonia was produced by creatinine decomposition.

106 Serum creatinine decreased more (by 0.17 mg/dL [95% CI, 0.06-0

107 transplanted from deceased donors with serum creatinine-defined acute kidney injury (AKI) have simila

108 nical donor AKI (elevated biomarkers without creatinine-defined AKI) and GF.

109 We examined if serum creatinine-defined donor AKI modified this association t

110 the Kidney Disease Improving Global Outcomes creatinine definition) within a moving 48-hour window.

111 s of height-adjusted total kidney volume and creatinine-derived eGFR.

112 h H(2), plasma glucose and urinary galactose/creatinine) discriminated between lactase persistence (L

113 ment for age, sex, comorbidities, diagnosis, creatinine, diuresis, and study.

114 points (albuminuria and a composite of serum creatinine doubling or 40% estimated glomerular filtrati

115 was typically mild relative to the degree of creatinine elevation.

116 ipid, HbA1c (glycosylated hemoglobin), serum creatinine, eosinophils, lymphocyte, monocytes, neutroph

117 ic Kidney Disease Epidemiology Collaboration creatinine equation.

118 eported plasma levels and urinary and plasma creatinine estimates.

119 s assessed as accurate by comparing measured creatinine excretion rate (CER) to CER estimated using a

120 with those determined using formaldehyde and creatinine fluorometric assay kits.

121 AKI is defined using changes in creatinine from baseline.

122 ea and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with reni

123 g on the stage of CKD: Group 1 (clearance of creatinine > 75 mL/min) patients with no renal disease (

124 s of 8-OHdG >50 ng/mg of creatinine or urine creatinine >1.5 mg minimized screen failures, with 91% s

125 5, 95% confidence interval [CI], 1.83-6.14), creatinine >10.1 mg/L (OR, 3.22, 2.28-4.54), and urea ni

126 defined using KDIGO guidelines and terminal creatinine >= 1.5 mg/dL.

127 criteria (age >=80 years, weight <=60 kg, or creatinine >=1.5 mg/dl [133 mumol/l]) were randomized to

128 .14-0.98; P = 0.04), and high baseline serum creatinine (hazard ratio, 4.12; SD, 1.7-10.3; P = 0.002)

129 ge, previous IHD and diabetes, Killip class, creatinine, hemoglobin and troponin on admission, sympto

130 tional grafts with an elevation in the serum creatinine; however, our group and others found this ext

131 FR (HR 1.5, p = 0.001) and doubling of serum creatinine (HR 2.0, p < 0.001).

132 rmin protected against AKI, with lower serum creatinine, improved histological changes and decreased

133 decrease in the ratio of urinary cortisol to creatinine in children younger than 8 years of age.

134 her (with albumin measured in milligrams and creatinine in grams) or an eGFR decrease of at least 3.0

135 of formaldehyde in human whole blood and of creatinine in saliva, and also for the real-time monitor

136 in the low-risk group and 55 +/- 11 ng/mg of creatinine in the high-risk group.

137 owed alteration of serum creatine kinase and creatinine in the Leu389Ser ALS4 cohort.

138 ns in study patients were 22 +/- 10 ng/mg of creatinine in the low-risk group and 55 +/- 11 ng/mg of

139 pt for an increased additional rise in serum creatinine in the plazomicin arm compared with the merop

140 riable logistic regression revealed baseline creatinine in umol/L (odds ratio 0.99 [95% confidence in

141 Creatinine increases >0.5 mg/dL over baseline only occur

142 r was highly selective to glucose, urea, and creatinine interferences.

143 uring the 0% fat-fast (1.05 +/- 0.39 mumol/g creatinine) intervention (compared with 0% fat, P = 0.00

144 reatinine) and 0% fat (2.37 +/- 0.37 mumol/g creatinine) interventions were similar, but a ~50% decre

145 mical reactions for detecting creatinine and creatinine is an important biomarker for chronic kidney

146 An elevated terminal creatinine is frequently used as a reason for organ refu

147 Serum creatinine is not a direct indicator of renal injury, ra

148 iously published data; a high donor terminal creatinine is not significantly associated with DGF in p

149 Because creatinine is ubiquitous in proteinaceous foods, the con

150 panel reactive antibody, donor types, donor creatinine, ischemic time, and immunosuppression regimen

151 ochemical platform for the quantification of creatinine; it showed a dynamic range of 3.25-200 muM an

152 ndary MR in the COAPT trial were lower serum creatinine, KCCQ-OS score and MitraClip treatment.

153 .9 +/- 4.2%) and cardiac damage (% change in creatinine kinase, 49.3 +/- 41.3 vs. 214.6 +/- 155.1; al

154 acid and lower levels of L-acetylcarnitine, creatinine, L-asparagine, L-glutamine, linoleic acid, py

155 r, including median age (68 years) and serum creatinine level (305.5 and 273.5 umol/L in BD and C-BD

156 eplacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04).

157 estimated glomerular filtration rate, serum creatinine level, and the risk for hemodialysis and meta

158 ddition to biochemical indices such as serum creatinine level, are promising biomarkers to track the

159 nute per 1.73 m(2)), a doubling of the serum creatinine level, or death from renal or cardiovascular

160 CI, 1.001-1.026]; p = 0.032), and increased creatinine levels (odds ratio, 1.012 [95% CI, 1.006-1.01

161 patients with pre-LT cardiovascular disease, creatinine levels 12 months after LT significantly impac

162 ents with COVID-19 were older and had higher creatinine levels and less favorable vital signs.

163 d a new predictive model that combines serum creatinine levels and maximum liver function capacity (L

164 hanges on CT or electroencephalogram, higher creatinine levels and receive dialysis, but had longer d

165 Male recipients of female donor kidneys had creatinine levels at 1 year that were 6.3% higher (95% C

166 Serum creatinine levels from baseline and within day 5 or disc

167 While creatinine levels in the blood seem to provide better in

168 Younger age and higher proteinuria and serum creatinine levels increased the likelihood that the pati

169 Because race and sex affect serum creatinine levels independently of GFR, the earlier crea

170 Drifting of serum creatinine levels over time should also be taken into co

171 Serum creatinine levels tended to mildly increase (3% bezafibr

172 , reduced neutrophil infiltration, and serum creatinine levels were apparent.

173 Blood urea nitrogen (BUN) and creatinine levels were similar to untreated mice, demons

174 Peripheral mononuclear cells, serum creatinine levels, and renal biopsies were collected fro

175 rum fasting glucose, haemoglobin A1c levels, creatinine levels, and the urinary albumin-to-creatinine

176 isting heart failure, diabetes mellitus, and creatinine levels, apnea-hypopnea index was independentl

177 rformances, except in patients with unstable creatinine levels.

178 Donors with elevated terminal creatinine likely resulting from acute kidney injury (AK

179 s of moderate CKD, including elevated plasma creatinine, lower hematocrit, and increased intact parat

180 ith no or resolved AKI stage 1 plus terminal creatinine < 1.5 mg/dL.

181 enal disease (n = 67); Group 3 (clearance of creatinine < 10 mL/min) patients on hemodialysis (n = 40

182 ate by chronic kidney disease (CKD)-EPI-CysC-creatinine <60 mL/min/1.73 m at WL inclusion was an inde

183 thout hypertension or diabetes, and terminal creatinine <= 4 mg/dL.

184 tio (with albumin measured in milligrams and creatinine measured in grams) of 30 to less than 300, an

185 d participants using a field-based capillary creatinine measuring system and collected self-reported

186 an absolute or a relative increase in serum creatinine of >0.3 mg/dl or >=50%, respectively, or the

187 s had good allograft function, with a median creatinine of 1.2 mg/dl and median eGFR of 57 ml/min per

188 grafts have done well, with an average serum creatinine of 1.45 mg/dL at 2 years (range 1.01-1.85 mg/

189 enal disease (n = 24); Group 2 (clearance of creatinine of 11-75 mL/min) patients with renal disease

190 stimation of glomerular filtration rate with creatinine or cystatin C-based standard and kinetic equa

191 AKI, defined as a >=2-fold increase in serum creatinine or new dialysis requirement directly attribut

192 ficant difference in the recipient discharge creatinine or the likelihood of developing DGF.

193 reening cutoff values of 8-OHdG >50 ng/mg of creatinine or urine creatinine >1.5 mg minimized screen

194 onor kidney injury, measured by either serum creatinine or urine injury biomarkers.

195 revealed peak AST (OR, 2.8; P = .0019), peak creatinine (OR, 7.3; P = .0065), and SOFA (Sequential Or

196 further affect body weight, blood pressure, creatinine, or hematocrit in either group.

197 ory rate; elevated levels of venous lactate, creatinine, or procalcitonin; or low platelet or lymphoc

198 y attenuated after adjusting for cord plasma creatinine (P = 0.05).

199 o normoalbuminuria (0.0442 vs 0.0103 nmol/mg creatinine, P < 0.0001), and increased ca. threefold in

200 ts with stable GFR (0.0561 vs 0.0176 nmol/mg creatinine, P < 0.01).

201 The mean creatinine percentage change was +5.2% (range, -6.7% to

202 d grade 3 rash (in two patients) and grade 3 creatinine phosphokinase elevation (in one patient) in t

203 dverse events were rash (11 [19%] patients), creatinine phosphokinase elevation (six [11%]), hypoalbu

204 ffects (grade 2 or worse diarrhoea, rash, or creatinine phosphokinase elevation).

205 e atezolizumab and control groups were blood creatinine phosphokinase increased (51.3% vs 44.8%), dia

206 CKD-progression (higher GFR and lower serum creatinine, proteinuria, kidney inflammatory infiltratio

207 sks, while the risk score for abnormal serum creatinine provided moderate discrimination (AUC, 0.62)

208 trial in patients with T2DM, urinary albumin-creatinine ratio >300 mg/g, and estimated glomerular fil

209 min per 1.73 m(2) per year, or urine albumin/creatinine ratio >=30 mg/g.

210 s duration, waist/hip ratio, urinary albumin/creatinine ratio (ACR) and fasting C-peptide.

211 Urine albumin-to-creatinine ratio (ACR) and protein-to-creatinine ratio (

212 filtration rate (eGFR) and urine albumin-to-creatinine ratio (ACR) at baseline.

213 Urinary albumin-to-creatinine ratio (ACR) is a marker of diabetic nephropat

214 iltration rate (eGFR) and urinary albumin-to-creatinine ratio (ACR), with cancer incidence.

215 identified 2 known loci for urine albumin-to-creatinine ratio (BCL2L11 rs116907128, P=5.6x10(-8) and

216 measures was cysC-eGFR and urine albumin-to-creatinine ratio (DeltaC=0.019 [95% CI, 0.015-0.022]).

217 HbA1c levels, urinary albumin-creatinine ratio (p = 0.041), average cell size and CV s

218 min-to-creatinine ratio (ACR) and protein-to-creatinine ratio (PCR) are used to measure urine protein

219 ngs with the exception of urinary albumin-to-creatinine ratio (Rg = 0.64; SE = 0.22; P = 0.0042), a b

220 ency=0.01, P=1.6x10(-8)) or urine albumin-to-creatinine ratio (rs527493184 at ZBTB16, minor allele fr

221 rognostic value of baseline urine albumin-to-creatinine ratio (uACR) and plasma soluble tumour necros

222 GWAS summary data for eGFR, urinary albumin-creatinine ratio (UACR), BUN, and serum urate.

223 lbuminuria was estimated by urine albumin-to-creatinine ratio (UACR); and M/I was estimated from stea

224 timated changes in eGFR and urine protein-to-creatinine ratio (UPCR) after 18 months using mixed-effe

225 ated urinary retinol-binding protein-urinary creatinine ratio (uRBP/uCr) and reduced BMD.

226 Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams an

227 acid 7.2 (5.8-8.7) mg/dL, and urine protein-creatinine ratio 0.11 (0.08-0.20) mg/mg.

228 ts with type 2 diabetes and urine albumin-to-creatinine ratio 30 to 5000 mg/g and an estimated glomer

229 tes, increased albuminuria (urine albumin-to-creatinine ratio [UACR] 30-3500 mg/g), an estimated glom

230 ed in 2006 to 2010 with the urine albumin-to-creatinine ratio and estimated glomerular filtration rat

231 Increased urine podocin/creatinine ratio in TG signifies accelerated podocyte lo

232 merular filtration rate and urine albumin-to-creatinine ratio in up to 12 207 Hispanics/Latinos.

233 no history of gout who had a urinary albumin:creatinine ratio of 265 or higher (with albumin measured

234 etinopathy, or they had a urinary albumin-to-creatinine ratio of 300 to 5000 and an eGFR of 25 to les

235 )) and validated 8 loci for urine albumin-to-creatinine ratio previously identified in the UK Biobank

236 ile range (IQR): 4.90-11.93] and the cadmium:creatinine ratio was 0.96 mug/g (IQR: 0.61-1.51).

237 ml/min/1.73 m2, and median urine albumin-to-creatinine ratio was 3.4 mg/mmol.

238 ble data (N = 687), the median urine arsenic:creatinine ratio was 7.54 mug/g [interquartile range (IQ

239 in hs-cTnI, CRP, uric acid, or urine protein-creatinine ratio were observed.

240 reatinine levels, and the urinary albumin-to-creatinine ratio were recorded.

241 (creat-eGFR, cysC-eGFR, and urine albumin-to-creatinine ratio) led to significant improvement in risk

242 a tubular marker (Urinary pellet aquaporin 2:creatinine ratio) were measured in macro-albuminuric, mi

243 r minute per 1.73 m(2); median urine albumin:creatinine ratio, 716.9; mean serum urate level, 8.2 mg

244 use, body mass index, urine microalbumin-to-creatinine ratio, and estimated glomerular filtration ra

245 Total urine output, urinary protein, albumin/creatinine ratio, flow rate, resistance were measured.

246 her systolic blood pressure, urinary albumin/creatinine ratio, RPTC apoptosis and urinary RPTCs than

247 ia over time, as measured by urinary protein:creatinine ratio.

248 dinal changes in eGFR and urinary albumin-to-creatinine ratio.

249 to which we added eGFR and urine albumin-to-creatinine ratio.

250 on of lymphocyte count with urine albumin-to-creatinine ratio.

251 oglobin A1c (HbA1c) levels and urine albumin creatinine ratio.

252 lectin-3, cystatin-C, and urinary albumin-to-creatinine ratio.

253 line eGFR, and higher baseline urine albumin/creatinine ratio.

254 cyte detachment (Urinary pellet podocin mRNA:creatinine ratio: UPPod:CR) and a tubular marker (Urinar

255 phrotic-range albuminuria with an albumin-to-creatinine-ratio (ACR) >220 mg/mmol was a significantly

256 bilirubin were independently associated with creatinine reported in mixed-effects models.

257 dney injury according to thresholds of serum creatinine rise.

258 d if, within 48 hours postoperatively, serum creatinine rose by 50% or by 0.3 mg/dL (26.5 mumol/L) fr

259 erular filtration rate (eGFR) based on serum creatinine (sCr) improves early after left ventricular a

260 h stable kidney function and available serum creatinine (SCr) measurement before and after imaging wh

261 Replacing serum creatinine (SCr) with estimated glomerular filtration ra

262 on GL and graft function, measured by serum creatinine (SCr), after pregnancy in KT recipients, stra

263 were correlated with changes in eGFR, serum creatinine (SCr), systolic blood pressure (SBP), renal h

264 I) equation for adults are recommended serum creatinine (SCr)-based calculations for estimating glome

265 eighted regression analysis, controlling for creatinine, sex, age, race, body mass index, and diet, s

266 Despite implementation of creatinine standardization, centers within a single UNOS

267 Despite implementation of creatinine standardization, centers within one UNOS regi

268 The serum level of creatinine starts to decrease before the onset of muscle

269 r half (56.2%) presented with elevated serum creatinine suggestive of acute kidney injury.

270 in these participants and confirmatory serum creatinine testing in phase 1 participants.

271 olled 222 new participants, performing serum creatinine testing in these participants and confirmator

272 for exclusive cigarette smokers (39.8 mug/g creatinine) than for non-users (3.05 mug/g creatinine).

273 When stratified by the donor terminal creatinine, there was no significant difference in the r

274 rent components of PELD and added sodium and creatinine to the equation.

275 tor: day from ICU admission, age, sex, serum creatinine, trauma, and cardiac surgery.

276 norNet was used to characterize longitudinal creatinine trends and urine output.

277 ations and oligomerizations of aldehydes and creatinine under usual cooking conditions.

278 ional status was analyzed by levels of serum creatinine, urea, cystatin-C, and urea creatinine.

279 analysis measurements can be used to predict creatinine/urea clearance based on 24 hours urine collec

280 rated to be constant over the whole range of creatinine/urea clearance based on 24 hours urine collec

281 r" more than 71% of the observed variance in creatinine/urea clearance based on 24 hours urine collec

282 unger than 18 years old who had at least two creatinine values measured during a hospital admission f

283 Pre-MRI creatinine values ranged from 0.32 to 6.57 mg/dL (median

284 Serum creatinine values within 180 days or less of each GA MRI

285 Median serum creatinine was 1.8 mg/dL and 0.8 mg/dL in patients with

286 Donor creatinine was 10.18 mg/dl with protein (30 mg/dl) prese

287 Creatinine was not significantly different after the pro

288 The impact of serum creatinine was restricted to patients with pre-LT cardio

289 Any increase in serum creatinine was seen in 697 (36.1%) and acute kidney inju

290 er cold ischemia time but not donor terminal creatinine were independent predictors of DGF.

291 hereas values obtained for urinary galactose/creatinine were lower than the existing literature cut-o

292 glomerular filtration rate (eGFR) and serum creatinine were noted.

293 Reaction mixtures of reactive carbonyls and creatinine were submitted to high temperature and studie

294 Plasma glucose and urinary galactose/creatinine were unreliable (AUC < 0.70) after milk inges

295 in class 2 at 24 months postdiagnosis; serum creatinine with persistence: 2.48 mg/dL vs 1.65 with cle

296 d POC testing for viral load, CD4 count, and creatinine, with task shifting from professional to lowe

297 analysis confirmed bilirubin interfered with creatinine, with worsening agreement in creatinine at hi

298 KI as a 0.3 mg/dl absolute increase in serum creatinine within 48 hours, or >=1.5-fold relative eleva

299 IQx was produced by reaction of acrolein and creatinine within a wide pH range and with an activation

300 There was a transient rise in his serum creatinine without change in urine output; dialysis was